Matches in Wikidata for { <http://www.wikidata.org/entity/Q86270026> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q86270026 description "clinical trial" @default.
- Q86270026 description "ensayu clínicu" @default.
- Q86270026 description "klinisch onderzoek" @default.
- Q86270026 description "клінічне випробування" @default.
- Q86270026 name "First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration" @default.
- Q86270026 name "First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration" @default.
- Q86270026 type Item @default.
- Q86270026 label "First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration" @default.
- Q86270026 label "First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration" @default.
- Q86270026 prefLabel "First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration" @default.
- Q86270026 prefLabel "First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration" @default.
- Q86270026 P1050 Q86270026-44502EDA-0C70-414E-8A29-5C4809351349 @default.
- Q86270026 P1050 Q86270026-767BC830-E2A4-4CC1-8A65-7526C79A4354 @default.
- Q86270026 P1050 Q86270026-C9D6801D-76A5-4080-999A-B552829EA837 @default.
- Q86270026 P1132 Q86270026-4F75E258-F3B7-4069-AC8B-CFEEE0654C56 @default.
- Q86270026 P1476 Q86270026-48792837-B5C8-41A2-8D5F-9D4C7A989AC2 @default.
- Q86270026 P17 Q86270026-9267036D-1172-45FA-B60B-557B014EFC03 @default.
- Q86270026 P2899 Q86270026-AE25B659-DC6A-4BEF-8F6A-ECC18DB923A6 @default.
- Q86270026 P3098 Q86270026-89508C3E-AE65-4FD6-86BE-EA35C83B191B @default.
- Q86270026 P31 Q86270026-A53C1C2F-B05C-48FC-8527-0323B2020866 @default.
- Q86270026 P580 Q86270026-0158171E-29FF-44EC-AF6D-4B1A4F6CC365 @default.
- Q86270026 P582 Q86270026-20A3476E-B2BC-45A7-837F-CC081A563761 @default.
- Q86270026 P6099 Q86270026-324F8A5D-3FC3-4F22-B624-12289B33691D @default.
- Q86270026 P8363 Q86270026-FF46C0ED-25F4-43A4-B27A-5E453FAA3512 @default.
- Q86270026 P1050 Q194520 @default.
- Q86270026 P1050 Q27429789 @default.
- Q86270026 P1050 Q3043268 @default.
- Q86270026 P1132 "+12" @default.
- Q86270026 P1476 "A Phase 1, Multicenter, Open-label, Single-dose, Dose-escalation Study in Patients With Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Intravitreal Injections of GEM103" @default.
- Q86270026 P17 Q30 @default.
- Q86270026 P2899 "+50" @default.
- Q86270026 P3098 "NCT04246866" @default.
- Q86270026 P31 Q30612 @default.
- Q86270026 P580 "2019-12-19T00:00:00Z" @default.
- Q86270026 P582 "2020-05-01T00:00:00Z" @default.
- Q86270026 P6099 Q5452194 @default.
- Q86270026 P8363 Q78089383 @default.